keyword
MENU ▼
Read by QxMD icon Read
search

Bueso Ramos

keyword
https://www.readbyqxmd.com/read/27923552/preleukaemic-clonal-haemopoiesis-and-risk-of-therapy-related-myeloid-neoplasms-a-case-control-study
#1
Koichi Takahashi, Feng Wang, Hagop Kantarjian, Denaha Doss, Kanhav Khanna, Erika Thompson, Li Zhao, Keyur Patel, Sattva Neelapu, Curtis Gumbs, Carlos Bueso-Ramos, Courtney D DiNardo, Simona Colla, Farhad Ravandi, Jianhua Zhang, Xuelin Huang, Xifeng Wu, Felipe Samaniego, Guillermo Garcia-Manero, P Andrew Futreal
BACKGROUND: Therapy-related myeloid neoplasms are secondary malignancies that are often fatal, but their risk factors are not well understood. Evidence suggests that individuals with clonal haemopoiesis have increased risk of developing haematological malignancies. We aimed to identify whether patients with cancer who have clonal haemopoiesis are at an increased risk of developing therapy-related myeloid neoplasms. METHODS: We did this retrospective case-control study to compare the prevalence of clonal haemopoiesis between patients treated for cancer who later developed therapy-related myeloid neoplasms (cases) and patients who did not develop these neoplasms (controls)...
December 2, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27830539/primary-autoimmune-myelofibrosis-a-case-report-and-review-of-the-literature
#2
Yasmin Abaza, C Cameron Yin, Carlos E Bueso-Ramos, Sa A Wang, Srdan Verstovsek
Autoimmune myelofibrosis is a rare, distinct clinicopathological entity that can occur in isolation (primary) or in association with systemic autoimmune disorders (secondary), such as systemic lupus erythematosus and Sjogren's syndrome. This disease is characterized by isolated or combined chronic cytopenias associated with autoimmune phenomena and bone-marrow fibrosis. Due to the rarity of this disease, patients are frequently misdiagnosed as having primary myelofibrosis, the most common form of bone-marrow fibrosis...
November 9, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27813536/clinical-significance-of-trisomy-8-that-emerges-during-therapy-in-chronic-myeloid-leukemia
#3
W Wang, Z Chen, Z Hu, C C Yin, S Li, S Bai, C E Bueso-Ramos, L J Medeiros, S Hu
No abstract text is available yet for this article.
November 4, 2016: Blood Cancer Journal
https://www.readbyqxmd.com/read/27795561/a-clinical-trial-for-patients-with-acute-myeloid-leukemia-or-myelodysplastic-syndromes-not-eligible-for-standard-clinical-trials
#4
G Montalban-Bravo, X Huang, E Jabbour, G Borthakur, C D DiNardo, N Pemmaraju, J Cortes, S Verstovsek, T Kadia, N Daver, W Wierda, Y Alvarado, M Konopleva, F Ravandi, Z Estrov, N Jain, A Alfonso, M Brandt, T Sneed, H-C Chen, H Yang, C Bueso-Ramos, S Pierce, E Estey, Z Bohannan, H M Kantarjian, G Garcia-Manero
Most clinical trials exclude patients with poor performance or comorbidities. To study whether patients with these characteristics can be treated within a clinical trial, we conducted a study for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) with poor performance, organ dysfunction or comorbidities. Primary endpoint was 60-day survival. Study included stopping rules for survival and response. Treatment consisted on a combination of azacitidine and vorinostat. Thirty patients (16 with MDS, 14 with AML) were enrolled...
October 31, 2016: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/27755009/distinguishing-between-hepatosplenic-t-cell-lymphoma-and-%C3%AE-%C3%AE-t-cell-large-granular-lymphocytic-leukemia-a-clinicopathologic-immunophenotypic-and-molecular-analysis
#5
Mariko Yabe, L Jeffrey Medeiros, Sa A Wang, Guilin Tang, Carlos E Bueso-Ramos, Jeffrey L Jorgensen, Govind Bhagat, Weina Chen, Shaoying Li, Ken H Young, Roberto N Miranda
Hepatosplenic T-cell lymphoma (HSTCL) is a rare, aggressive T-cell lymphoma that can be challenging to diagnose. In particular, distinguishing HSTCL from T-cell large granular lymphocytic (T-LGL) leukemia of γδ T-cell receptor (TCR) type is difficult without examination of a splenectomy specimen. In this study, we systematically assessed a series of HSTCL cases for findings reported in the literature as supporting or not supporting the diagnosis of HSTCL. We also compared HSTCL with a group of cases of T-LGL of γδ TCR type...
October 13, 2016: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/27741352/phase-2-study-of-low-dose-clofarabine-plus-cytarabine-for-patients-with-higher-risk-myelodysplastic-syndrome-who-have-relapsed-or-are-refractory-to-hypomethylating-agents
#6
Elias Jabbour, Stefan Faderl, Koji Sasaki, Tapan Kadia, Naval Daver, Naveen Pemmaraju, Keyur Patel, Joseph D Khoury, Carlos Bueso-Ramos, Zachary Bohannan, Farhad Ravandi, Gautam Borthakur, Srdan Verstovsek, Darla Miller, Rita Maduike, Chitra Hosing, Hagop M Kantarjian, Guillermo Garcia-Manero
BACKGROUND: The outcome of patients with higher risk myelodysplastic syndromes (MDS) after hypomethylating agent (HMA) failure is poor. This study evaluated the safety and activity of a combination of low-dose clofarabine and cytarabine for these patients. METHODS: Seventy patients with higher risk MDS who had no response, progressed, or relapsed after at least 4 cycles of HMA therapy were treated. RESULTS: The median age was 72 years. Thirty-nine percent of the patients had high-risk disease according to the International Prognostic Scoring System, and 50% of the patients had poor-risk cytogenetics...
October 14, 2016: Cancer
https://www.readbyqxmd.com/read/27741105/well-differentiated-systemic-mastocytosis-showed-excellent-clinical-response-to-imatinib-in-the-absence-of-known-molecular-genetic-abnormalities-a-case-report
#7
Lanshan Huang, Sa A Wang, Sergej Konoplev, Carlos E Bueso-Ramos, Beenu Thakral, Roberto N Miranda, Elias Jabbour, L Jeffrey Medeiros, Rashmi Kanagal-Shamanna
INTRODUCTION: Well-differentiated systemic mastocytosis (WDSM) is a rare, recently recognized provisional subvariant of systemic mastocytosis (SM). We report a case of WDSM that showed excellent clinical and cutaneous response to imatinib in the absence of known molecular genetic abnormalities. CLINICAL FINDINGS/DIAGNOSES: We present a 24-year-old woman with childhood onset of skin manifestations that progressed to mediator-related systemic events, and a gastrointestinal tract mastocytoma...
October 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27739436/p53-expression-correlates-with-poorer-survival-and-augments-the-negative-prognostic-effect-of-myc-rearrangement-expression-or-concurrent-myc-bcl2-expression-in-diffuse-large-b-cell-lymphoma
#8
Xuan J Wang, L Jeffrey Medeiros, Carlos E Bueso-Ramos, Guilin Tang, Sa Wang, Yasuhiro Oki, Parth Desai, Joseph D Khoury, Roberto N Miranda, Zhenya Tang, Nishitha Reddy, Shaoying Li
In patients with diffuse large B-cell lymphoma, MYC rearrangement (MYC-R), MYC expression, or concurrent expression of MYC and BCL2 is associated with a poorer prognosis. P53 expression also has been shown to confer inferior survival in diffuse large B-cell lymphoma patients, but less is known about the role of P53 expression in those with MYC-R, MYC expression (MYC+), or MYC&BCL2 co-expression (MYC+/BCL2+). We studied P53 expression in 201 patients with untreated de novo diffuse large B-cell lymphoma. Sixty-seven (33%) cases were P53 positive, 56 (28%) had MYC-R (including 17 MYC/BCL2 double hit lymphoma), 86 (45%) were MYC+/BCL2+, and 47 (24%) were positive for both MYC and P53...
October 14, 2016: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/27521332/multiparameter-analysis-of-off-target-effects-of-dasatinib-on-bone-homeostasis-in-patients-with-newly-diagnosed-chronic-myelogenous-leukemia
#9
Daniela Hoehn, Jorge E Cortes, L Jeffrey Medeiros, Elias J Jabbour, Juliana E Hidalgo, Rashmi Kanagal-Shamanna, Carlos E Bueso-Ramos
BACKGROUND: We assessed patients with chronic myelogenous leukemia (CML) for serum calcium (Ca), phosphate (PO4), bone alkaline phosphatase, N-telopeptide (NTx), osteoprotegerin (OPG) levels, and trabecular bone area (TBA) in bone marrow (BM) specimens before and after treatment with dasatinib. We identified a significant increase in percentage of TBA in postdasatinib BM (P = .022). This suggests that dasatinib therapy can increase TBA without significant changes in bone and mineral metabolism...
August 2016: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/27508525/prognostic-significance-of-day-14-bone-marrow-evaluation-in-adults-with-philadelphia-chromosome-negative-acute-lymphoblastic-leukemia
#10
Nicholas J Short, Hagop M Kantarjian, Koji Sasaki, Jorge E Cortes, Farhad Ravandi, Deborah A Thomas, Guillermo Garcia-Manero, Issa Khouri, Partow Kebriaei, Richard E Champlin, Sherry Pierce, Ghayas C Issa, Marina Konopleva, Tapan M Kadia, Carlos Bueso-Ramos, Joseph D Khoury, Nitin Jain, Susan M O'Brien, Elias Jabbour
BACKGROUND: The role of day 14 (D14) bone marrow (BM) assessment in detecting increased blasts in patients undergoing induction for acute lymphoblastic leukemia (ALL) is not well defined. METHODS: This study evaluated 389 adolescent and adult patients with previously untreated Philadelphia chromosome-negative ALL who received frontline induction chemotherapy and for whom a D14 BM assessment was performed. RESULTS: A D14 BM blast proportion < 10% (including blast-free aplastic BM) was observed in 319 patients (82%), 10% to 29% was observed in 31 patients (8%), and ≥30% was observed in 39 patients (10%)...
December 15, 2016: Cancer
https://www.readbyqxmd.com/read/27496109/donor-derived-t-cell-large-granular-lymphocytic-leukemia-in-a-patient-with-peripheral-t-cell-lymphoma
#11
Juliana E Hidalgo Lopez, Mariko Yabe, Adrian A Carballo-Zarate, Sa A Wang, Jeffrey L Jorgensen, Sairah Ahmed, John Lee, Shaoying Li, Ellen Schlette, Timothy McDonnell, Roberto N Miranda, L Jeffrey Medeiros, Carlos E Bueso-Ramos, C Cameron Yin
T-cell large granular lymphocytic (T-LGL) leukemia after hematopoietic stem cell transplantation (SCT) is rare and its natural history and clinical outcome have not been well described. We report the clinical, morphologic, immunophenotypic, and molecular features of a case of donor-derived T-LGL leukemia in a 16-year-old man who received allogeneic SCT for peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). The patient presented with persistent neutropenia and splenomegaly 9 months after SCT when the chimerism study showed a 100% donor pattern...
August 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27318442/double-minute-chromosomes-in-acute-myeloid-leukemia-myelodysplastic-syndromes-and-chronic-myelomonocytic-leukemia-are-associated-with-micronuclei-myc-or-mll-amplification-and-complex-karyotype
#12
Yang O Huh, Guilin Tang, Sameer S Talwalkar, Joseph D Khoury, Maro Ohanian, Carlos E Bueso-Ramos, Lynne V Abruzzo
Double minute chromosomes (dmin) are small, paired chromatin bodies that lack a centromere and represent a form of extrachromosomal gene amplification. Dmin are rare in myeloid neoplasms and are generally associated with a poor prognosis. Most studies of dmin in myeloid neoplasms are case reports or small series. In the current study, we present the clinicopathologic and cytogenetic features of 22 patients with myeloid neoplasms harboring dmin. These neoplasms included acute myeloid leukemia (AML) (n = 18), myelodysplastic syndrome (MDS) (n = 3), and chronic myelomonocytic leukemia (CMML) (n = 1)...
July 2016: Cancer Genetics
https://www.readbyqxmd.com/read/27312067/peripheral-t-cell-lymphomas-of-follicular-helper-t-cell-type-frequently-display-an-aberrant-cd3-dim-cd4-population-by-flow-cytometry-an-important-clue-to-the-diagnosis-of-a-hodgkin-lymphoma-mimic
#13
Mir Alikhan, Joo Y Song, Aliyah R Sohani, Julien Moroch, Anne Plonquet, Amy S Duffield, Michael J Borowitz, Liuyan Jiang, Carlos Bueso-Ramos, Kedar Inamdar, Madhu P Menon, Sandeep Gurbuxani, Ernest Chan, Sonali M Smith, Alina Nicolae, Elaine S Jaffe, Philippe Gaulard, Girish Venkataraman
Nodal follicular helper T-cell-derived lymphoproliferations (specifically the less common peripheral T-cell lymphomas of follicular type) exhibit a spectrum of histologic features that may mimic reactive hyperplasia or Hodgkin lymphoma. Even though angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma of follicular type share a common biologic origin from follicular helper T-cells and their morphology has been well characterized, flow cytometry of peripheral T-cell lymphomas of follicular type has not been widely discussed as a tool for identifying this reactive hyperplasia/Hodgkin lymphoma mimic...
October 2016: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/27291887/a-novel-description-of-a-syndrome-consisting-of-7q21-3-deletion-including-dync1i1-with-preserved-dlx5-6-without-ectrodactyly-a-case-report
#14
Héctor M Ramos-Zaldívar, Daniel G Martínez-Irías, Nelson A Espinoza-Moreno, José S Napky-Rajo, Tulio A Bueso-Aguilar, Karla G Reyes-Perdomo, Jimena A Montes-Gambarelli, Isis M Euceda, Aldo F Ponce-Barahona, Carlos A Gámez-Fernández, Wilberg A Moncada-Arita, Victoria A Palomo-Bermúdez, Julia E Jiménez-Faraj, Amanda G Hernández-Padilla, Denys A Olivera, Kevin J Robertson, Luis A Leiva-Sanchez, Edwin Francisco Herrera-Paz
BACKGROUND: Chromosomal region 7q21.3 comprises approximately 5.2 mega base pairs that include genes DLX5/6, SHFM1, and DYNC1I1 associated with split hand/split foot malformation 1. So far, there are reports of eight families with deletion of DYNC1I1 and preserved DLX5/6 associated with ectrodactyly. From these families, only three patients did not present ectrodactyly and, unlike our patient, no other cases have been described as having craniofacial dysmorphology, mitral valve prolapse, kyphoscoliosis, inguinal herniae, or personality disorder...
2016: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/27203548/prognostic-impact-of-history-of-follicular-lymphoma-induction-regimen-and-stem-cell-transplant-in-patients-with-myc-bcl2-double-hit-lymphoma
#15
Shaoying Li, Annapurna Saksena, Parth Desai, Jie Xu, Zhuang Zuo, Pei Lin, Guilin Tang, C Cameron Yin, Adam Seegmiller, Jeffrey L Jorgensen, Roberto N Miranda, Nishitha M Reddy, Carlos Bueso-Ramos, L Jeffrey Medeiros
MYC/BCL2 double hit lymphoma (DHL) has been the subject of many studies; however, no study has systemically compared the clinicopathologic features and prognostic factors between patients with de novo disease versus those with a history of follicular lymphoma (FL). In addition, the prognostic importance of several other issues remains controversial in these patients. In this retrospective study, we assess 157 patients with MYC/BCL2 DHL including 108 patients with de novo disease and 49 patients with a history of FL or rarely other types of low-grade B-cell lymphoma...
June 21, 2016: Oncotarget
https://www.readbyqxmd.com/read/27174585/targeted-next-generation-sequencing-identifies-a-subset-of-idiopathic-hypereosinophilic-syndrome-with-features-similar-to-chronic-eosinophilic-leukemia-not-otherwise-specified
#16
Sa A Wang, Wayne Tam, Albert G Tsai, Daniel A Arber, Robert P Hasserjian, Julia T Geyer, Tracy I George, David R Czuchlewski, Kathryn Foucar, Heesun J Rogers, Eric D Hsi, B Bryan Rea, Adam Bagg, Paola Dal Cin, Chong Zhao, Todd W Kelley, Srdan Verstovsek, Carlos Bueso-Ramos, Attilio Orazi
The distinction between chronic eosinophilic leukemia, not otherwise specified and idiopathic hypereosinophilic syndrome largely relies on clonality assessment. Prior to the advent of next-generation sequencing, clonality was usually determined by cytogenetic analysis. We applied targeted next-generation sequencing panels designed for myeloid neoplasms to bone marrow specimens from a cohort of idiopathic hypereosinophilic syndrome patients (n=51), and assessed the significance of mutations in conjunction with clinicopathological features...
August 2016: Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc
https://www.readbyqxmd.com/read/27155969/high-expression-of-human-homologue-of-murine-double-minute-4-and-the-short-splicing%C3%A2-variant-hdm4-s-in-bone-marrow-in%C3%A2-patients-with-acute-myeloid-leukemia-or-myelodysplastic-syndrome
#17
REVIEW
Xin Han, L Jeffrey Medeiros, Yu Helen Zhang, M James You, Michael Andreeff, Marina Konopleva, Carlos E Bueso-Ramos
The human homologue of murine double minute 2 (HDM2) and HDM4 negatively regulate p53. HDM4 has not been assessed in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). We examined the expression of HDM4 and the short splicing variant, HDM4-S, in bone marrow samples obtained from 85 and 23 patients with AML and MDS, respectively, and 18 negative tumor staging bone marrow samples (used as the control). Immunohistochemical staining showed that HDM4 was overexpressed in 78 AML cases (92%) and 12 MDS cases (52%) compared with 1 stressed bone marrow sample (6%)...
August 2016: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/27130145/advances-in-b-lymphoblastic-leukemia-cytogenetic-and-genomic-lesions
#18
REVIEW
Yi Zhou, Rashmi Kanagal-Shamanna, Zhuang Zuo, Guilin Tang, L Jeffrey Medeiros, Carlos E Bueso-Ramos
No abstract text is available yet for this article.
August 2016: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/27124925/myeloproliferative-neoplasms-with-calreticulin-mutations-exhibit-distinctive-morphologic-features
#19
Sanam Loghavi, Carlos E Bueso-Ramos, Rashmi Kanagal-Shamanna, Chi Young Ok, Alaa A Salim, Mark J Routbort, Meenakshi Mehrotra, Srdan Verstovsek, L Jeffrey Medeiros, Rajyalakshmi Luthra, Keyur P Patel
OBJECTIVES: Calreticulin (CALR) mutations are present in 50% to 85% of JAK2/MPL wild-type (wt) myeloproliferative neoplasms (MPNs). The histopathologic features of CALR-mutated MPNs are unknown. METHODS: We identified 71 patients with essential thrombocythemia (ET), primary myelofibrosis (PMF), and post-essential thrombocythemia myelofibrosis (post-ET MF) with available CALR status. CALR was assessed using capillary electrophoresis followed by Sanger sequencing confirmation...
March 2016: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/27049467/aberrant-hnrnp-k-expression-all-roads-lead-to-cancer
#20
Miguel Gallardo, Marisa J Hornbaker, Xiaorui Zhang, Peter Hu, Carlos Bueso-Ramos, Sean M Post
The classification of a gene as an oncogene or a tumor suppressor has been a staple of cancer biology for decades. However, as we delve deeper into the biology of these genes, this simple classification has become increasingly difficult for some. In the case of heterogeneous nuclear ribonuclear protein K (hnRNP K), its role as a tumor suppressor has recently been described in acute myeloid leukemia and demonstrated in a haploinsufficient mouse model. In contrast, data from other clinical correlation studies suggest that hnRNP K may be more fittingly described as an oncogene, due to its increased levels in a variety of malignancies...
June 17, 2016: Cell Cycle
keyword
keyword
72750
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"